Villepinte, March 13, 2017 - Guerbet takes note of the recommendations issued by the Pharmacovigilance Risk Assessment Committee (PRAC), on Gadolinium-based Contrast Agents - procedure under Article 31 of Directive 2001/83/EC.
28/02/2017 ECR 2017: Guerbet will be there!
ECR 2017 | Expo Hall X2 – Booth 21 | from March 1 to 5 | Austria Center Vienna ӏ Vienna (Austria)
16/02/2017 Explore 90 years of passion on guerbet90.com
As part of the “90 Years of Passion” campaign, Guerbet is launching a website, guerbet90.com, on the birth date of its founder, André Guerbet.
27/11/2015 Guerbet completes acquisition of Mallinckrodt’s Contrast Media and Delivery Systems business (CMDS)
Guerbet announces that it has completed its acquisition of the "contrast media and delivery systems" (CMDS) business of Mallinckrodt. The new entity brings together 2,500 employees, with a pro forma turnover of about €800M.
On Thursday, October 22, Frost & Sullivan honoured recipients of "2015 Excellence in Best Practices Awards". FlowSens®, Guerbet innovative injection solution, received the "2015 European Contrast Auto-injector-CT Imaging Modality New Product Innovation Award"
27/10/2015 Fresh success for Guerbet at JFR 2015
Four days of meetings, 160 staff present, interventional radiology post-graduate training and a highly appreciated symposium on the topic of gadolinium deposits in the brain
Guerbet announced today that it has entered into a definitive agreement under which it will acquire Mallinckrodt’s contrast media and delivery systems business (“CMDS”). With this acquisition, Guerbet aims to create a new global leader in medical imaging. Read the press release